Celldex Therapeutics, Inc. (NASDAQ:CLDX) Shares Sold by Octagon Capital Advisors LP

Octagon Capital Advisors LP trimmed its position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 6.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 707,526 shares of the biopharmaceutical company’s stock after selling 52,372 shares during the period. Celldex Therapeutics makes up about 4.5% of Octagon Capital Advisors LP’s holdings, making the stock its 7th largest holding. Octagon Capital Advisors LP owned about 1.50% of Celldex Therapeutics worth $28,060,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Strs Ohio boosted its stake in shares of Celldex Therapeutics by 92.9% in the fourth quarter. Strs Ohio now owns 2,700 shares of the biopharmaceutical company’s stock valued at $107,000 after purchasing an additional 1,300 shares during the period. Aigen Investment Management LP purchased a new position in Celldex Therapeutics in the 4th quarter valued at approximately $251,000. Panoramic Investment Advisors LLC acquired a new position in shares of Celldex Therapeutics in the fourth quarter worth $258,000. Victory Capital Management Inc. purchased a new stake in shares of Celldex Therapeutics during the fourth quarter worth $288,000. Finally, Values First Advisors Inc. acquired a new stake in shares of Celldex Therapeutics in the fourth quarter valued at $293,000.

Insider Buying and Selling

In other Celldex Therapeutics news, SVP Diane C. Young sold 45,000 shares of the firm’s stock in a transaction dated Friday, June 7th. The stock was sold at an average price of $35.26, for a total transaction of $1,586,700.00. Following the transaction, the senior vice president now owns 2,115 shares of the company’s stock, valued at $74,574.90. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In other Celldex Therapeutics news, SVP Diane C. Young sold 45,000 shares of Celldex Therapeutics stock in a transaction that occurred on Friday, June 7th. The stock was sold at an average price of $35.26, for a total transaction of $1,586,700.00. Following the transaction, the senior vice president now owns 2,115 shares of the company’s stock, valued at $74,574.90. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, VP Elizabeth Crowley sold 38,597 shares of the stock in a transaction that occurred on Thursday, May 30th. The shares were sold at an average price of $33.64, for a total value of $1,298,403.08. Following the completion of the sale, the vice president now directly owns 9,074 shares of the company’s stock, valued at $305,249.36. The disclosure for this sale can be found here. Insiders have sold 219,160 shares of company stock worth $7,501,489 in the last ninety days. 3.80% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research analysts recently commented on CLDX shares. Cantor Fitzgerald reissued an “overweight” rating and set a $67.00 target price on shares of Celldex Therapeutics in a research note on Friday, March 22nd. Guggenheim upped their target price on shares of Celldex Therapeutics from $72.00 to $90.00 and gave the stock a “buy” rating in a research note on Tuesday, February 27th. HC Wainwright reiterated a “buy” rating and issued a $80.00 price target on shares of Celldex Therapeutics in a research note on Monday, June 3rd. Finally, Wolfe Research started coverage on shares of Celldex Therapeutics in a research report on Tuesday. They issued an “outperform” rating and a $51.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $63.00.

Celldex Therapeutics Price Performance

Shares of NASDAQ CLDX opened at $34.67 on Friday. The stock’s 50-day simple moving average is $37.76 and its 200-day simple moving average is $38.86. Celldex Therapeutics, Inc. has a fifty-two week low of $22.11 and a fifty-two week high of $53.18.

Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings data on Monday, May 6th. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.11. Celldex Therapeutics had a negative net margin of 2,385.57% and a negative return on equity of 29.55%. The company had revenue of $0.16 million for the quarter, compared to analysts’ expectations of $1.30 million. As a group, research analysts predict that Celldex Therapeutics, Inc. will post -2.32 earnings per share for the current fiscal year.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.